Literature DB >> 6396399

Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid.

P J Worland, O H Drummer, B Jarrott.   

Abstract

The gastric and intestinal absorption of captopril, an orally active angiotensin-converting enzyme inhibitor was determined using rat in situ gastric pouch and intestinal loop techniques and compared with the absorption of another acidic drug, salicylic acid, whose absorption has been well established from both gastric and intestinal sites. Captopril absorption was determined at two initial intraluminal concentrations in acute (untreated) rats and in rats that had been chronically treated with captopril. Salicylic acid absorption was determined at one concentration in acute rats. During the 40-min experimental period, captopril absorption at the 4.6 mM dose from the gastric pouch was 17.0 +/- 1.8% and 17.9 +/- 5.4% in acute and chronically treated rats, respectively, and 33.6 +/- 9.2% and 23.7 +/- 7.6%, respectively, from the intestinal loop. At the 11.5 mM dose the captopril absorption in 40 min was 13.7 +/- 2.7% and 17.3 +/- 4.2% from the gastric pouch of acutely and chronically treated rats, respectively, and 17.8 +/- 4.2% and 22.9 +/- 3.3%, respectively, from the intestinal loop. As similar fractions of the different administered doses were absorbed from the respective gastric and intestinal sites in both acutely and chronically treated rats, the absorption process of captopril appears to be principally by passive diffusion and unaffected by chronic administration of captopril. In comparison, salicylic acid was absorbed more rapidly and to a greater extent from both the gastric and intestinal preparations. The percent of salicylic acid absorbed into the plasma at the 11.5 mM dose was 44.8 +/- 4.4% and 65.3 +/- 5.3% from the gastric and intestinal preparations, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6396399     DOI: 10.1002/jps.2600731224

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation.

Authors:  I R Wilding; S S Davis; M Bakhshaee; H N Stevens; R A Sparrow; J Brennan
Journal:  Pharm Res       Date:  1992-05       Impact factor: 4.200

2.  Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.

Authors:  Rana Rais; Randall Hoover; Krystyna Wozniak; Michelle A Rudek; Takashi Tsukamoto; Jesse Alt; Camilo Rojas; Barbara S Slusher
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

3.  Sustained Captopril-Induced Reduction in Blood Pressure Is Associated With Alterations in Gut-Brain Axis in the Spontaneously Hypertensive Rat.

Authors:  Tao Yang; Victor Aquino; Gilberto O Lobaton; Hongbao Li; Luis Colon-Perez; Ruby Goel; Yanfei Qi; Jasenka Zubcevic; Marcelo Febo; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

4.  Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration.

Authors:  Haicui Wu; Theo Y C Lam; Tim-Fat Shum; Tsung-Yu Tsai; Jiachi Chiou
Journal:  Hypertens Res       Date:  2021-12-02       Impact factor: 3.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.